Protective effects of ethanolic extract of Delphinium denudatum in a rat model of Parkinson's disease

Parkinson's disease (PD) is one of the major neurodegenerative disorders, and oxidative stress has been implicated in playing an important role in the pathogenesis of the disease. In the present study, we investigated if Delphinium denudatum extract can slow down the neuronal injury in 6-hydroxydopamine (6-OHDA) rat model of Parkinsonism. Rats were treated with 200, 400 and 600 mg/kg body weight (b.w.) of D. denudatum extract for 3 weeks. On day 22, 2 mL of 6-OHDA (10 mgin 0.1% ascorbic acid-saline) or vehicle was infused into the right striatum of the animals. Three weeks after the 6-OHDA injections, the rats were killed for estimation of lipid peroxidation (LPO), reduced glutathione (GSH) content, superoxide dismutase (SOD) and catalase (CAT) activities, catecholamines, dopaminergic D2 receptor binding and tyrosine hydroxylase (TH) expression. Increased LPO and significant depletion of reduced GSH content in the substantia nigra resulting from the lesion were appreciably prevented with Delphinium treatment. Delphinium extract also dose-dependently attenuated the activities of SOD and CAT in striatum, which had been reduced significantly by lesioning. A significant decrease in the level of dopamine (DA) and its metabolites and an increase in the number of dopaminergic D2 receptors in striatum were observed after 6-OHDA injection, both parameters were significantly recovered with treatment of the extract. Finally, all these results were confirmed by an increase in expression of TH in the ipsilateral striatum of the lesioned groups following treatment with Delphinium extract. Thus, the study indicates that D. denudatum extract may be helpful in checking neuronal injury in Parkinsonism.

[1]  J. P. Huston,et al.  UNILATERAL 6-HYDROXYDOPAMINE LESIONS OF MESO-STRIATAL DOPAMINE NEURONS AND THEIR PHYSIOLOGICAL SEQUELAE , 1996, Progress in Neurobiology.

[2]  D. Jollow,et al.  Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. , 1974, Pharmacology.

[3]  R. Angel,et al.  The Wealth of India , 1974 .

[4]  J. Clardy,et al.  Antifungal diterpenoid alkaloids from Delphinium denudatum. , 1997, Journal of natural products.

[5]  I. Fridovich Superoxide dismutases: an adaptation to a paramagnetic gas , 1989 .

[6]  Andreas Schober,et al.  Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP , 2004, Cell and Tissue Research.

[7]  Rajnish Kumar Chaturvedi,et al.  Ginkgo biloba affords dose‐dependent protection against 6‐hydroxydopamine‐induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences , 2005, Journal of neurochemistry.

[8]  J. Crapo,et al.  Biology of disease: free radicals and tissue injury. , 1982, Laboratory investigation; a journal of technical methods and pathology.

[9]  K. Chopra,et al.  DITERPENE ALKALOIDS. ISOLATION AND STUDY OF TWO NEW ALKALOIDS , 1962, The Journal of pharmacy and pharmacology.

[10]  M. Ahmad,et al.  Protective role of Delphinium denudatum (Jadwar) against morphine induced tolerance and dependence in mice. , 2001, Journal of ethnopharmacology.

[11]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[12]  J. Walrond,et al.  Effects of Delphinium alkaloids on neuromuscular transmission. , 1999, The Journal of pharmacology and experimental therapeutics.

[13]  Muzamil Ahmad,et al.  Protective effect of adenosine in rat model of Parkinson's disease: neurobehavioral and neurochemical evidences , 2003, Journal of Chemical Neuroanatomy.

[14]  Z. Shah,et al.  Ginkgo biloba normalises stress-elevated alterations in brain catecholamines, serotonin and plasma corticosterone levels , 2003, European Neuropsychopharmacology.

[15]  J. Cooper,et al.  Irreversible Inhibition of Mitochondrial Complex I by 1‐Methyl‐4‐Phenylpyridinium: Evidence for Free Radical Involvement , 1992, Journal of neurochemistry.

[16]  J. Cadet,et al.  Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain , 1992, Brain Research Bulletin.

[17]  Muzamil Ahmad,et al.  Dose‐dependent protective effect of selenium in rat model of Parkinson's disease: neurobehavioral and neurochemical evidences , 2003, Journal of neurochemistry.

[18]  Y. Sun,et al.  Free radicals, antioxidant enzymes, and carcinogenesis. , 1990, Free radical biology & medicine.

[19]  Y. Urade,et al.  Prostaglandin D2 formation and characterization of its synthetases in various tissues of adult rats. , 1988, Archives of biochemistry and biophysics.

[20]  P. Seth,et al.  Neurobehavioural, neurochemical and electrophysiological studies in 6-hydroxydopamine lesioned and neural transplanted rats , 1995, International Journal of Developmental Neuroscience.

[21]  D. F. Brown,et al.  Neuropathologic Evidence that the Lewy Body Variant of Alzheimer Disease Represents Coexistence of Alzheimer Disease and Idiopathic Parkinson Disease , 1995, Journal of neuropathology and experimental neurology.

[22]  Fred H. Gage,et al.  Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior , 1991, Brain Research.

[23]  A. Schober,et al.  Genes, proteins, and neurotoxins involved in Parkinson’s disease , 2004, Progress in Neurobiology.

[24]  I. Fridovich,et al.  Superoxide dismutase: improved assays and an assay applicable to acrylamide gels. , 1971, Analytical biochemistry.

[25]  M. Ansari,et al.  Neuroprotective effects of Withania somnifera on 6-hydroxydopamine induced Parkinsonism in rats , 2005, Human & experimental toxicology.

[26]  L. H. Keith,et al.  The structures of condelphine, isotalatizidine, and talatizidine. , 1967, Journal of the American Chemical Society.

[27]  Tajuddin,et al.  The anti-stress activity of a gem-containing Unani formulation against diverse stressors. , 1998, Journal of ethnopharmacology.

[28]  H. M. Said Hamdard Pharmacopoeia of Eastern Medicine , 1997 .

[29]  Greg A. Gerhardt,et al.  Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats , 1993, Brain Research.

[30]  J. L. SIMONSEN,et al.  The Wealth of India , 1949, Nature.

[31]  A. K. Agarwal,et al.  Free Radical‐Generated Neurotoxicity of 6‐Hydroxydopamine , 1995, Journal of neurochemistry.

[32]  G. C. Wagner,et al.  Methamphetamine-induced neuronal damage: A possible role for free radicals , 1989, Neuropharmacology.

[33]  X.-T. Hu,et al.  Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[34]  栄治 長谷川 1-methyl-4-phenylpyridinium (MPP[+]) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles , 1993 .

[35]  S. Sombati,et al.  Anticonvulsant activities of ethanolic extract and aqueous fraction isolated from Delphinium denudatum. , 2001, Journal of ethnopharmacology.

[36]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.